Katharina Strienke

Katharina Strienke

Auto-generated profile, based on publicly available information

Katharina Strienke

Institute for Biophysical Chemistry, Hannover Medical School, Hannover, Germany

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2024 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
TSTobias Schüning
Tobias Schüning
AZAndre Zeug
Andre Zeug
KSKatharina Strienke
Katharina Strienke
PFPeter Franz
Peter Franz
GTGeorgios Tsiavaliaris
Georgios Tsiavaliaris
Peter ClausPeter Claus
Peter Claus
Spinal Muscular Atrophy (SMA) is a neuromuscular disease caused by low levels of the Survival of Motoneuron (SMN) protein. SMN interacts with and regulates the actin‐binding protein profilin2a, thereby influencing actin dynamics. Dysfunctional actin dynamics caused by SMN loss disrupts neurite outgrowth, axonal pathfinding, and formation of functional synapses in neurons. Whether the SMN protein directly interacts with and regulates filamentous (F‐) and monomeric globular (G‐) actin is still elusive. In a quantitative single cell approach, we show that SMN loss leads to dysregulated F‐/G‐actin fractions. Furthermore, quantitative assessment of cell morphology suggests an F‐actin organizational defect. Interestingly, this is mediated by an interaction of SMN with G‐ and F‐actin. In co‐immunoprecipitation, in‐vitro pulldown and co‐localization assays, we elucidated that this interaction is independent of the SMN‐profilin2a interaction. Therefore, we suggest two populations being relevant for functional actin dynamics in healthy neurons: SMN‐profilin2a‐actin and SMN‐actin. Additionally, those two populations may influence each other and therefore regulate binding of SMN to actin. In SMA, we showed a dysregulated co‐localization pattern of SMN‐actin which could only partially rescued by SMN restoration. However, dysregulation of F‐/G‐actin fractions was reduced by SMN restoration. Taken together, our results suggest a novel molecular function of SMN in binding to actin independent from SMN‐profilin2a interaction.

16 November 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
DKDespoina Kyriazi
Despoina Kyriazi
LVLea Voth
Lea Voth
ABAlmke Bader
Almke Bader
WEWiebke Ewert
Wiebke Ewert
JGJuliane Gerlach
Juliane Gerlach
GTGeorgios Tsiavaliaris
Georgios Tsiavaliaris
Aberrant Ras homologous (Rho) GTPase signalling is a major driver of cancer metastasis, and GTPase-activating proteins (GAPs), the negative regulators of RhoGTPases, are considered promising targets for suppressing metastasis, yet drug discovery efforts have remained elusive. Here, we report the identification and characterization of adhibin, a synthetic allosteric inhibitor of RhoGAP class-IX myosins that abrogates ATPase and motor function, suppressing RhoGTPase-mediated modes of cancer cell metastasis. In human and murine adenocarcinoma and melanoma cell models, including three-dimensional spheroid cultures, we reveal anti-migratory and anti-adhesive properties of adhibin that originate from local disturbances in RhoA/ROCK-regulated signalling, affecting actin-dynamics and actomyosin-based cell-contractility. Adhibin blocks membrane protrusion formation, disturbs remodelling of cell-matrix adhesions, affects contractile ring formation, and disrupts epithelial junction stability; processes severely impairing single/collective cell migration and cytokinesis. Combined with the non-toxic, non-pathological signatures of adhibin validated in organoids, mouse and Drosophila models, this mechanism of action provides the basis for developing anti-metastatic cancer therapies.